amantadine has been researched along with Mental Disorders in 33 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with schizophrenia (Sch), schizoaffective, schizophreniform, or bipolar (BP) I disorders [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)]; not manic or acutely psychotic [Brief Psychiatric Rating Scale (BPRS) total score < or =45]; treated with olanzapine for 1-24 months; and who had gained > or =5% of their initial body weight were examined to determine whether amantadine could attenuate weight gain or promote weight loss." | 9.11 | Amantadine for weight gain associated with olanzapine treatment. ( Breier, A; Bymaster, FP; Carlson, CD; Cavazzoni, PA; Deberdt, W; Floris, M; Trzaskoma, QN; Wiener, K; Winokur, A, 2005) |
| "The purpose of this study was to explore whether amantadine would slow or reverse significant weight gain in children and adolescents treated with antipsychotics and/or mood stabilizers that may promote increases in weight." | 7.71 | Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. ( Gracious, BL; Krysiak, TE; Youngstrom, EA, 2002) |
| "Patients with schizophrenia (Sch), schizoaffective, schizophreniform, or bipolar (BP) I disorders [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)]; not manic or acutely psychotic [Brief Psychiatric Rating Scale (BPRS) total score < or =45]; treated with olanzapine for 1-24 months; and who had gained > or =5% of their initial body weight were examined to determine whether amantadine could attenuate weight gain or promote weight loss." | 5.11 | Amantadine for weight gain associated with olanzapine treatment. ( Breier, A; Bymaster, FP; Carlson, CD; Cavazzoni, PA; Deberdt, W; Floris, M; Trzaskoma, QN; Wiener, K; Winokur, A, 2005) |
| "The purpose of this study was to explore whether amantadine would slow or reverse significant weight gain in children and adolescents treated with antipsychotics and/or mood stabilizers that may promote increases in weight." | 3.71 | Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. ( Gracious, BL; Krysiak, TE; Youngstrom, EA, 2002) |
| "The drug treatment of Parkinson's disease has progressed through 3 main stages: firstly, the use of anticholinergic drugs and amantadine; then the introduction of levodopa and its association with peripheral decarboxylase inhibitors; and finally the use of direct acting dopamine agonist drugs." | 2.37 | Anti-parkinsonian drugs today. ( Quinn, NP, 1984) |
| "Subacute sclerosing panencephalitis (SSPE) is a progressive neurodegenerative disease caused by persistent infection of the brain with the measles virus." | 1.51 | Adult-Onset Subacute Sclerosing Panencephalitis Presented with Neuropsychiatric Symptoms. ( Gokoglu, A; Gozdas, HT, 2019) |
| " The anti-influenza virus drug oseltamivir has been reported to have several pharmacological actions including blocking of nicotinic acetylcholine receptor channels and activation of the dopaminergic system." | 1.48 | [Similarity of Clinically Significant Neuropsychiatric Adverse Reactions Listed in Package Inserts between the Anti-influenza Drugs Oseltamivir and Amantadine (Possibility Attributable to Common Pharmacological Effects)]. ( Fukushima, A; Okamura, M; Ono, H, 2018) |
| "Amantadine has a growing body of evidence for the treatment of aggressive behavior in patients with traumatic brain injury, autism spectrum disorder, and developmental disability." | 1.43 | Adjunctive Amantadine Treatment for Aggressive Behavior in Children: A Series of Eight Cases. ( Loveland, JG; McGrane, IR; Zaluski, HJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (45.45) | 18.7374 |
| 1990's | 2 (6.06) | 18.2507 |
| 2000's | 10 (30.30) | 29.6817 |
| 2010's | 6 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ono, H | 1 |
| Okamura, M | 1 |
| Fukushima, A | 1 |
| Gokoglu, A | 1 |
| Gozdas, HT | 1 |
| Pagonabarraga, J | 1 |
| Kulisevsky, J | 1 |
| Plantier, D | 1 |
| Luauté, J | 1 |
| McGrane, IR | 1 |
| Loveland, JG | 1 |
| Zaluski, HJ | 1 |
| Michalski, LS | 1 |
| Hantsch Bardsley, C | 1 |
| Holt, DR | 1 |
| Milner, JE | 1 |
| Hou, SH | 1 |
| Stacy, M | 1 |
| Regragui, W | 1 |
| Lachhab, L | 1 |
| Razine, R | 1 |
| Benjelloun, H | 1 |
| Ait Benhaddou, EH | 1 |
| Benomar, A | 1 |
| Yahyaoui, M | 1 |
| Gracious, BL | 1 |
| Krysiak, TE | 1 |
| Youngstrom, EA | 1 |
| Kamitani, W | 1 |
| Tomonaga, K | 1 |
| Ikuta, K | 1 |
| Deberdt, W | 1 |
| Winokur, A | 1 |
| Cavazzoni, PA | 1 |
| Trzaskoma, QN | 1 |
| Carlson, CD | 1 |
| Bymaster, FP | 1 |
| Wiener, K | 1 |
| Floris, M | 1 |
| Breier, A | 1 |
| Arciniegas, DB | 1 |
| Frey, KL | 1 |
| Anderson, CA | 1 |
| Brousseau, KM | 1 |
| Harris, SN | 1 |
| Howland, RH | 1 |
| Rao, V | 1 |
| Handel, S | 1 |
| Vaishnavi, S | 1 |
| Keach, S | 1 |
| Robbins, B | 1 |
| Spiro, J | 1 |
| Ward, J | 1 |
| Berlin, F | 1 |
| Quinn, NP | 1 |
| Parkes, JD | 1 |
| Terao, T | 1 |
| Keller Ashton, A | 1 |
| Hamer, R | 1 |
| Rosen, RC | 1 |
| Lieb, K | 1 |
| Staeheli, P | 1 |
| Biéder, J | 1 |
| Gehlen, W | 1 |
| Gonce, M | 1 |
| Barbeau, A | 1 |
| Dolezalová, B | 1 |
| Vacek, J | 1 |
| Peiró Grasa, A | 1 |
| Grau-Veciana, JM | 1 |
| Rappaport, M | 1 |
| Calne, DB | 1 |
| Reid, JL | 1 |
| Rinne, UK | 1 |
| Diehl, LW | 1 |
| Lhermitte, F | 1 |
| Degos, CF | 1 |
| Vitetta, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Amantadine for Neuroenhancement in Acute Patients Study - A Prospective Pilot Proof of Concept Phase IIb Study in Intensive and Intermediate Care Unit Patients[NCT05479032] | Phase 2 | 50 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for amantadine and Mental Disorders
| Article | Year |
|---|---|
[Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].
Topics: Amantadine; Antiparkinson Agents; Cardiovascular Diseases; Catechol O-Methyltransferase; Catechol O- | 2014 |
Drugs for behavior disorders after traumatic brain injury: Systematic review and expert consensus leading to French recommendations for good practice.
Topics: Adrenergic beta-Antagonists; Amantadine; Anticonvulsants; Antidepressive Agents; Antipsychotic Agent | 2016 |
Consensus conference. Treatment of hepatitis C.
Topics: Adult; Aged; Alcoholism; Amantadine; Antiviral Agents; Body Weight; Child; Drug Therapy, Combination | 2002 |
[Borna disease virus infection].
Topics: Amantadine; Animals; Antibodies, Viral; Antiviral Agents; Borna Disease; Borna disease virus; Brain; | 2003 |
Glutamate-modulating drugs & the treatment of mental disorders.
Topics: Acamprosate; Amantadine; Cycloserine; Glutamic Acid; Humans; Ketamine; Lamotrigine; Memantine; Menta | 2007 |
Anti-parkinsonian drugs today.
Topics: Amantadine; Amphetamines; Antiparkinson Agents; Brain Chemistry; Catechol O-Methyltransferase Inhibi | 1984 |
Adverse effects of antiparkinsonian drugs.
Topics: Amantadine; Amphetamines; Antiparkinson Agents; Dyskinesia, Drug-Induced; Ergot Alkaloids; Humans; H | 1981 |
Borna disease virus--does it infect humans and cause psychiatric disorders?
Topics: Amantadine; Animals; Antibodies, Viral; Antiviral Agents; Borna Disease; Borna disease virus; Brain; | 2001 |
[Iatrogenic damage possibilities in the drug therapy of neurologic and psychiatric diseases].
Topics: Amantadine; Anticonvulsants; Barbiturates; Benzodiazepines; Carbamazepine; Central Nervous System Di | 1977 |
[The current treatment of Parkinson's disease].
Topics: Amantadine; Antidepressive Agents, Tricyclic; Dihydroxyphenylalanine; Drug Combinations; Histamine A | 1976 |
Antiparkinsonian drugs: pharmacological and therapeutic aspects.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Amantadine; Amphetamine; Antiparkinson Agents; Apomorphi | 1972 |
Recent advances in the treatment of Parkinsonism with drugs.
Topics: Amantadine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Arrhythmias, Cardiac; Blood-Brain | 1972 |
1 trial available for amantadine and Mental Disorders
| Article | Year |
|---|---|
Amantadine for weight gain associated with olanzapine treatment.
Topics: Adolescent; Adult; Aged; Amantadine; Analysis of Variance; Antiparkinson Agents; Antipsychotic Agent | 2005 |
20 other studies available for amantadine and Mental Disorders
| Article | Year |
|---|---|
[Similarity of Clinically Significant Neuropsychiatric Adverse Reactions Listed in Package Inserts between the Anti-influenza Drugs Oseltamivir and Amantadine (Possibility Attributable to Common Pharmacological Effects)].
Topics: Amantadine; Antiviral Agents; Dopamine Agonists; Drug Labeling; Enzyme Inhibitors; Humans; Influenza | 2018 |
Adult-Onset Subacute Sclerosing Panencephalitis Presented with Neuropsychiatric Symptoms.
Topics: Amantadine; Antiviral Agents; Brain; Electroencephalography; Female; Humans; Magnetic Resonance Imag | 2019 |
Adjunctive Amantadine Treatment for Aggressive Behavior in Children: A Series of Eight Cases.
Topics: Aggression; Amantadine; Child; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; In | 2016 |
Altered mental status in a transplant patient. Amantadine toxicity.
Topics: Adult; Amantadine; Confusion; Diabetes Complications; Diabetes Mellitus, Type 1; Female; Hallucinati | 2009 |
Medical treatment of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cognition Disorders; Corp | 2009 |
Profile of multiple system atrophy in Moroccan patients attending a movement disorders outpatient clinic in Rabat university hospital.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Amantadine; Disease Progression; Dopamine Agonists; Fe | 2013 |
Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series.
Topics: Adolescent; Amantadine; Analysis of Variance; Child; Female; Humans; Male; Mental Disorders; Psychot | 2002 |
Amantadine for neurobehavioural deficits following delayed post-hypoxic encephalopathy.
Topics: Adult; Amantadine; Brain; Brain Injuries; Cognition Disorders; Demyelinating Diseases; Diazepam; Dop | 2004 |
Psychiatric sequelae of traumatic brain injury: a case report.
Topics: Adult; Amantadine; Brain Injuries; Clinical Protocols; Cognition Disorders; Cognitive Behavioral The | 2007 |
Titration of serotonin reuptake blockers.
Topics: Amantadine; Drug Administration Schedule; Fluoxetine; Humans; Mental Disorders; Recurrence; Selectiv | 1993 |
Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large-scale retrospective study of 596 psychiatric outpatients.
Topics: Adult; Amantadine; Ambulatory Care; Aphrodisiacs; Cyproheptadine; Dopamine Agents; Female; Humans; M | 1997 |
[Cases of Huntington's chorea observed in a psychiatric setting: remarks on therapy].
Topics: Adult; Amantadine; Female; Humans; Huntington Disease; Male; Mental Disorders; Middle Aged; Penicill | 1975 |
[Modern antiparkinsonics (L-dopa and amantadine) and presentday psychiatry (author's transl)].
Topics: Amantadine; Humans; Levodopa; Mental Disorders; Parkinson Disease, Secondary; Psychotic Disorders | 1976 |
[Secondary effects of prolonged levodopa therapy in Parkinson's disease].
Topics: Age Factors; Aged; Amantadine; Antidepressive Agents, Tricyclic; Aromatic Amino Acid Decarboxylase I | 1985 |
Mental health research at a state hospital. An attempt at a balanced program.
Topics: Amantadine; Attitude of Health Personnel; Auditory Perception; Behavior Therapy; Computers; Conditio | 1968 |
["Nil nocere." Side effects during treatment of Parkinson's disease with amantadine].
Topics: Aged; Amantadine; Cognition Disorders; Edema; Eyelids; Female; Fingers; Foot; Hand; Humans; Kidney; | 1972 |
[Drug therapy of Parkinson's diseases].
Topics: Amantadine; Dihydroxyphenylalanine; Gastrointestinal Diseases; Humans; Hypotension, Orthostatic; Men | 1972 |
Levodopa and related drugs.
Topics: Amantadine; Apomorphine; Dihydroxyphenylalanine; Humans; Hydrazines; Hypotension; Mental Disorders; | 1973 |
[Effects of amantadine on the state of consciousness in diffuse cerebral psychosyndromes caused by vascular disorders].
Topics: Aged; Amantadine; Cerebrovascular Disorders; Female; Humans; Intracranial Arteriosclerosis; Male; Me | 1971 |
Preventing flu.
Topics: Aged; Amantadine; Humans; Influenza Vaccines; Influenza, Human; Isoquinolines; Mental Disorders | 1969 |